Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
IBI-325 / Innovent Biologics
Promise, NCT06081907: The Efficacy and Safety of IBI363 in Solid Tumors	Recruiting	1/2	430	RoW	IBI363, IBI325, Lenvatinib	Hunan Province Tumor Hospital, Xiangya Hospital of Central South University	Advanced Solid Tumor	12/26	09/28
NCT05246995: A Phase I Study of IBI325 in Patients With Advanced Solid Tumor	Not yet recruiting	1	60	RoW	IBI325+Sintilimab	Shandong Cancer Hospital and Institute	Solid Tumor	03/23	11/23
NCT05119998: A Phase I Study of IBI325 in Patients With Advanced Solid Tumor	Completed	1	48	RoW	IBI325 + sintilimab, IBI325	Innovent Biologics (Suzhou) Co. Ltd.	Solid Tumor	07/23	08/23